文献速递脑血管病认知障碍与痴呆

阿尔茨海默病合并房颤患者的抗凝治疗成本效果分析

Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
PubMed 文献 · Stroke · 2018-01-01

该研究采用微观模拟模型,从美国社会视角评估70岁阿尔茨海默病合并房颤患者终身成本与质量调整生命年,比较华法林与多种直接口服抗凝药。结果显示,社区居住的轻度AD患者使用艾多沙班具有成本效果,但中重度AD或长期护理机构患者中DOACs均不具成本效果,且所有口服抗凝药相比阿司匹林均不具成本效果。

要点

  • 社区轻度AD合并房颤患者,艾多沙班相比华法林具成本效果。
  • 中重度AD或长期护理机构患者,DOACs相比华法林不具成本效果。
  • 所有口服抗凝药相比阿司匹林在AD合并房颤患者中均不具成本效果。

核心结论

  • 社区居住的轻度AD合并房颤患者,艾多沙班相比华法林具成本效果。
  • 中重度AD社区患者及任何阶段AD长期护理机构患者,DOACs相比华法林不具成本效果。
  • 相比阿司匹林,华法林或任何DOAC在AD合并房颤患者中均不具成本效果。

研究设计与样本

  • 研究采用微观模拟模型,从美国社会视角估算70岁AD合并房颤患者终身成本、QALYs和成本效果。
  • 模型按AD阶段和护理环境分层,参数来自二次来源,支付意愿阈值为每QALY 10万美元。

主要发现

  • 所有患者组中DOACs相比华法林均增加QALYs,范围0.019至0.085。

临床怎么用

  • 社区居住的轻度AD合并房颤患者可优先考虑艾多沙班抗凝以平衡成本与获益。
  • 中重度AD或长期护理机构患者,处方DOACs需考虑经济性,华法林可能仍为合理选择。
  • 不推荐用阿司匹林替代口服抗凝药用于AD合并房颤患者的卒中预防。

局限性

  • 模型参数来源于二次来源,可能影响结果外推。
  • 分析基于美国社会视角,其他卫生体系下成本效果可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Direct oral anticoagulants (DOACs) are safer, at least equally efficacious, and cost-effective compared to warfarin for stroke prevention in atrial fibrillation (AF) but they remain underused, particularly in demented patients. We estimated the cost-effectiveness of DOACs compared with warfarin in patients with AF and Alzheimer's disease (AD). Methods- We constructed a microsimulation model to estimate the lifetime costs, quality-adjusted life-years (QALYs), and cost-effectiveness of anticoagulation therapy (adjusted-dose warfarin and various DOACs) in 70-year-old patients with AF and AD from a US societal perspective. We stratified patient cohorts based on stage of AD and care setting. Model parameters were estimated from secondary sources. Health benefits were measured in the number of acute health events, life-years, and QALYs gained. We classified alternatives as cost-effective using a willingness-to-pay threshold of $100 000 per QALY gained. Results- For patients with AF and AD, compared with warfarin, DOACs increase costs but also increase QALYs by reducing the risk of stroke. For mild-AD patients living in the community, edoxaban increased lifetime costs by $6603 and increased QALYs by 0.076 compared to warfarin, yielding an incremental cost-effectiveness ratio of $86 882/QALY gained. Even though DOACs increased QALYs compared with warfarin for all patient groups (ranging from 0.019 to 0.085 additional QALYs), no DOAC treatment alternative had an incremental cost-effectiveness ratio <$150 000/QALY gained for patients with moderate to severe AD. For patients living in a long-term care facility with mild AD, the DOAC with the lowest incremental cost-effectiveness ratio (rivaroxaban) costs $150 169 per QALY gained; for patients with more severe AD, the incremental cost-effectiveness ratios were higher. Conclusions- For patients with AF and mild AD living in the community, edoxaban is cost-effective compared with warfarin. Even though patients with moderate and severe AD living in the community and patients with any stage of AD living in a long-term care setting may obtain positive clinical benefits from anticoagulation treatment, DOACs are not cost-effective compared with warfarin for these populations. Compared to aspirin, no oral anticoagulation (warfarin or any DOAC) is cost effective in patients with AF and AD.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ruiz Vargas E, Sposato LA, Lee SAW, et al. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease. Stroke. 2018. PMID: 30571418. doi:10.1161/STROKEAHA.118.022596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。